Information about school immunization requirements and data

This table will no longer be updated after 5/30/2024 given the end of the 2023-2024 viral respiratory vaccine season.

This table shows the cumulative number and percentage of CT residents who have received an updated COVID-19 vaccine during the 2023-2024 viral respiratory season by age group (current age).
CDC recommends that people get at least one dose of this vaccine to protect against serious illness, whether or not they have had a COVID-19 vaccination before. Children and people with moderate to severe immunosuppression might be recommended more than one dose. For more information on COVID-19 vaccination recommendations, click here.
• Data are reported weekly on Thursday and include doses administered to Saturday of the previous week (Sunday – Saturday). All data in this report are preliminary. Data from the previous week may be changed because of delays in reporting, deduplication, or correction of errors.
• These analyses are based on data reported to CT WiZ which is the immunization information system for CT. CT providers are required by law to report all doses of vaccine administered. CT WiZ also receives records on CT residents vaccinated in other jurisdictions and by federal entities which share data with CT Wiz electronically. Electronic data exchange is being added jurisdiction-by-jurisdiction. Currently, this includes Rhode Island and New York City but not Massachusetts and New York State. Therefore, doses administered to CT residents in neighboring towns in Massachusetts and New York State will not be included. A full list of the jurisdiction with which CT has established electronic data exchange can be seen at the bottom of this page (https://portal.ct.gov/immunization/Knowledge-Base/Articles/Vaccine-Providers/CT-WiZ-for-Vaccine-Providers-and-Training/Query-and-Response-functionality-in-CT-WiZ?language=en_US)
• Population size estimates used to calculate cumulative percentages are based on 2020 DPH provisional census estimates*.
• People are included if they have an active jurisdictional status in CT WiZ at the time weekly data are pulled. This excludes people who live out of state, are deceased and a small percentage who have opted out of CT WiZ.
* DPH Provisional State and County Characteristics Estimates April 1, 2020. Hayes L, Abdellatif E, Jiang Y, Backus K (2022) Connecticut DPH Provisional April 1, 2020, State Population Estimates by 18 age groups, sex, and 6 combined race and ethnicity groups. Connecticut Department of Public Health, Health Statistics & Surveillance, SAR, Hartford, CT.

Morocco MA: Immunization: Measles: % of Children Aged 12-23 Months data was reported at 99.000 % in 2016. This stayed constant from the previous number of 99.000 % for 2015. Morocco MA: Immunization: Measles: % of Children Aged 12-23 Months data is updated yearly, averaging 92.000 % from Dec 1982 (Median) to 2016, with 35 observations. The data reached an all-time high of 99.000 % in 2016 and a record low of 17.000 % in 1982. Morocco MA: Immunization: Measles: % of Children Aged 12-23 Months data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Morocco – Table MA.World Bank: Health Statistics. Child immunization, measles, measures the percentage of children ages 12-23 months who received the measles vaccination before 12 months or at any time before the survey. A child is considered adequately immunized against measles after receiving one dose of vaccine.; ; WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).; Weighted average;

United States SB: MA: COVID Test/Vaccine: Proof of COVID Vaccination: No data was reported at 77.600 % in 11 Apr 2022. This records an increase from the previous number of 73.900 % for 04 Apr 2022. United States SB: MA: COVID Test/Vaccine: Proof of COVID Vaccination: No data is updated weekly, averaging 72.700 % from Nov 2021 (Median) to 11 Apr 2022, with 18 observations. The data reached an all-time high of 77.600 % in 11 Apr 2022 and a record low of 65.500 % in 03 Jan 2022. United States SB: MA: COVID Test/Vaccine: Proof of COVID Vaccination: No data remains active status in CEIC and is reported by U.S. Census Bureau. The data is categorized under Global Database’s United States – Table US.S049: Small Business Pulse Survey: by State: Northeast Region: Weekly, Beg Monday (Discontinued).

United States SB: MA: COVID Test/Vaccine: Proof of COVID Vaccination: N/A data was reported at 13.200 % in 11 Apr 2022. This records a decrease from the previous number of 14.100 % for 04 Apr 2022. United States SB: MA: COVID Test/Vaccine: Proof of COVID Vaccination: N/A data is updated weekly, averaging 14.050 % from Nov 2021 (Median) to 11 Apr 2022, with 18 observations. The data reached an all-time high of 19.100 % in 14 Mar 2022 and a record low of 9.000 % in 22 Nov 2021. United States SB: MA: COVID Test/Vaccine: Proof of COVID Vaccination: N/A data remains active status in CEIC and is reported by U.S. Census Bureau. The data is categorized under Global Database’s United States – Table US.S049: Small Business Pulse Survey: by State: Northeast Region: Weekly, Beg Monday (Discontinued).

The following dashboards provide data on contagious respiratory viruses, including acute respiratory diseases, COVID-19, influenza (flu), and respiratory syncytial virus (RSV) in Massachusetts. The data presented here can help track trends in respiratory disease and vaccination activity across Massachusetts.

Morocco MA: Immunization: HepB3: % of One-Year-Old Children data was reported at 99.000 % in 2016. This stayed constant from the previous number of 99.000 % for 2015. Morocco MA: Immunization: HepB3: % of One-Year-Old Children data is updated yearly, averaging 96.500 % from Dec 1999 (Median) to 2016, with 18 observations. The data reached an all-time high of 99.000 % in 2016 and a record low of 10.000 % in 1999. Morocco MA: Immunization: HepB3: % of One-Year-Old Children data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Morocco – Table MA.World Bank: Health Statistics. Child immunization rate, hepatitis B is the percentage of children ages 12-23 months who received hepatitis B vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized after three doses.; ; WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).; Weighted average;

United States SB: MA: COVID Test/Vaccine: Negative COVID Test: No data was reported at 80.500 % in 11 Apr 2022. This records a decrease from the previous number of 80.700 % for 04 Apr 2022. United States SB: MA: COVID Test/Vaccine: Negative COVID Test: No data is updated weekly, averaging 76.450 % from Nov 2021 (Median) to 11 Apr 2022, with 18 observations. The data reached an all-time high of 82.800 % in 15 Nov 2021 and a record low of 66.100 % in 10 Jan 2022. United States SB: MA: COVID Test/Vaccine: Negative COVID Test: No data remains active status in CEIC and is reported by U.S. Census Bureau. The data is categorized under Global Database’s United States – Table US.S049: Small Business Pulse Survey: by State: Northeast Region: Weekly, Beg Monday (Discontinued).

The growth of the poultry industry in Nigeria is constrained by major poultry diseases, despite the implementation of vaccination programs. This study aimed to assess the level of protection against Newcastle disease (ND), infectious bursal disease (IBD), and avian infectious bronchitis (IB) afforded by current vaccination schedules and characterize the circulating virus strains in commercial poultry flocks in Nigeria. A cross-sectional study was conducted on 44 commercial poultry farms in Oyo and Kano states of Nigeria. Serum and tissue samples and data on flock, clinical and vaccination records were collected on each farm. Farms were classified as being protected or not protected against ND, IBD and IB based on a defined criterion. Real-time reverse transcription polymerase chain reaction (rRT-PCR) testing was performed for each target virus on tissue samples and positive samples were sequenced. A total of 15/44 (34.1%), 35/44 (79.5%), and 1/44 (2.3%) farms were considered to be protected against ND, IBD, and IB, respectively, at the time of sampling. NDV RNA was detected on 7/44 (15.9%) farms and sequences obtained from 3/7 farms were characterized as the lentogenic strain. Infectious bursal disease virus (IBDV) RNA was detected on 16/44 (36.4%) farms tested; very virulent (vv) IBDV and non-virulent (nv) IBDV strains were both detected in 3/16 (18.8%) positive samples. Sequences of IBDV isolates were either clustered with a group of genotype 3 virulent IBDV strains or were related to vaccine strains MB and D78 strains. IBV RNA was detected on 36/44 (81.8%) farms, with variant02, Massachusetts, 4/91, and Q1 variants detected. Sequences of IBV isolates were either clustered with the vaccines strains Massachusetts M41 and H120 or were most closely related to the D274-like strains or a clade of sequences reported in Nigeria and Niger in 2006 and 2007. This study revealed that most study farms in Oyo and Kano states did not have adequate protective antibody titers against IBV and NDV and were therefore at risk of field challenge. Infectious bursal disease virus and IBV RNA were detected on farms with a history of vaccination suggesting potential vaccination failure, or that the vaccine strains used mismatch with the circulating strains and are therefore not protective.

A multi-adjuvant personal neoantigen vaccine generates potent immunity in melanoma (Cell, 2025)

Eryn Blass^1,5,17, Derin B. Keskin^{1, 3, 4, 5, 6, 7,17}, Chloe R. Tu^{1, 2}, Cleo Forman^{1, 2}, Allison Vanasse³, Haley E. Sax¹, Bohoon Shim², Vipheaviny Chea³, Nawoo Kim³, Isabel Carulli³, Jackson Southard³, Haoxiang Lyu³, Wesley Lu^{3, 16}, Micah Rickles-Young⁴, Alexander B. Afeyan^{1, 5}, Oriol Olive¹, Ambica Mehndiratta¹, Haley Greenslade¹, Keerthi Shetty¹, Joanna Baginska^{1, 8}, Ilana Gomez Diaz^{1, 8}, Allison Nau^{2, 8}, Kathleen L. Pfaff⁸, Andrew Gans⁸, Srinika Ranasinghe⁸, Elizabeth I. Buchbinder^{1, 5, 9}, Tamara A. Sussman^{1, 5, 9}, Megan L Insco^{1, 5, 9}, Charles H. Yoon^{1, 5, 10}, Scott J. Rodig^5,11, Sachet A. Shukla^3,16, Shuqiang Li^1,3,4 , Jon C. Aster^{5, 11}, David A. Braun^{1, 12, 13}, Carrie Cibulskis⁴, Nir Hacohen^{4, 5, 14}, Donna S. Neuberg², Anita Giobbie-Hurder², Kenneth J. Livak³, Edward F. Fritsch^{1, 4}, Giacomo Oliveira^1,4,5, Jeremy M. Simon^{2, 15}, Catherine J. Wu^{1, 4, 5, 9}, Patrick A. Ott^{1, 4, 5, 8, 9, 18,*}

Affiliations:

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA

² Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, 02215, USA

³ Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, 02215, USA

⁴ Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA

⁵Harvard Medical School, Boston, MA, 02215, USA

⁶Department of Computer Science, Metropolitan College, Boston University, Boston, MA, 02215, USA

⁷Section for Bioinformatics, Department of Health Technology, Technical University of Denmark, 2800 Lyngby, Denmark.

⁸ Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA

⁹Department of Medicine, Brigham and Women’s Hospital, Boston, MA, 02215, USA

¹⁰ Department of Surgery, Brigham and Women’s Hospital, Boston, MA, 02215, USA

¹¹ Department of Pathology, Brigham and Women’s Hospital, Boston, MA, 02215, USA

¹² Section of Medical Oncology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, 06511, USA

¹³Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, 06511, USA

¹⁴ Massachusetts General Hospital, Krantz Family Center for Cancer Research, Boston, MA, 02114 USA

¹⁵ Department of Biostatistics, Harvard T.H. Chan School of Public Health, 02215, USA

¹⁶ Current address: Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA

¹⁷ These authors contributed equally

¹⁸ Lead Contact

*Correspondence: Patrick_Ott@dfci.harvard.edu (P.A.O)

ABSTRACT

Personalized neoantigen-targeting vaccines have demonstrated great promise, however improved immunogenicity is still needed. Since antigen availability and effective T cell priming are critical for maximal immunogenicity, we tested a synthetic long peptide vaccine formulated with Montanide, poly-ICLC, and locally administered ipilimumab in addition to systemic nivolumab in 10 patients with melanoma. These personalized vaccines generated de novo ex vivo T cell responses against the majority of immunizing neoepitopes in all 9 fully vaccinated patients, and ex vivo CD8+ T cell responses in 6 of 9. Vaccination induced hundreds of circulating and intratumoral T cell receptor (TCR) clonotypes that were distinct from those arising after PD-1 inhibition. By linking the vaccine neoantigen specificity of T cell clonotypes with single cell phenotypes in tumors, we demonstrate remodeling of the intratumoral T cell repertoire following vaccination. These observations show that multi-pronged immune adjuvanticity can boost T cell responses to neoantigen-targeting vaccines.

This repository contains supplementary data files 1-5:

Data S1, List of patient mutations, related to Figure 1

Data S2, Supporting vaccine-site single-cell analysis data, related to Figure 2

Data S3, Supporting bulk-TCR clonotype analysis data, related to Figure 3

Data S4, Supporting tumor single-cell analysis data, related to Figure 4

Data S5, Supporting single-cell data for TCR reactivity assessment, related to Figure 5

Cumulative reports on mpox (formerly called monkeypox) cases and people vaccinated in Massachusetts.

Oligonucleotide mapping via liquid chromatography mass spectrometry mass spectrometry (LC-MS/MS) was recently developed to support development of Comirnaty®, the world’s first commercial mRNA vaccine which immunizes against the SARS-CoV-2 virus. Analogous to peptide mapping of therapeutic protein modalities, oligonucleotide mapping described here provides direct primary structure characterization of mRNA, through enzymatic digestion, accurate mass determinations, and optimized collisionally-induced fragmentation. Sample preparation for oligonucleotide mapping is a rapid, one-pot, one-enzyme digestion. The digest is analyzed via LC-MS/MS with an extended gradient and resulting data analysis employs semi-automated software. In a single method, oligonucleotide mapping readouts include a highly reproducible and completely annotated UV chromatogram with >98% sequence coverage and a microheterogeneity assessment of 5´ terminus capping and 3´ terminus poly(A) tail length. Oligonucleotide ma..., Oligonucleotide mapping was developed with a representative batch of Comirnaty® BNT162b2 Original DS (i.e., the original Pfizer-BioNTech COVID-19 vaccine that encodes for the spike glycoprotein (S) of the SARS-CoV-2 virus, the Wuhan-Hu-1 isolate: GenBank: QHD43416.1), and it has been applied to subsequent Comirnaty® BNT162b2 constructs (BNT162b2s04 [Delta] and BNT162b2s05 [Omicron]) and other portfolio mRNA molecules. Fifty micrograms of mRNA DS was digested with 2500 U of RNase T1 in a 50 mM Tris(hydroxymethyl)aminomethane (Tris) pH 7.5 buffer with 20 mM Ethylenediaminetetraacetic acid (EDTA) 1 h at 37°C. The resulting enzymatic fragment solution was spiked with 10× triethylamine (TEA) and 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) emulsion to give a final v/v concentration of 0.1% TEA 1% HFIP. A 4 µg load was injected and fragments were separated by ion-pair reversed-phase ultrahigh performance liquid chromatography (IP RP-UHPLC) with UV detection at 260 nm using a 1290 Infinity II Bio ..., The Thermo mass spectrometer .raw files can be opened by Xcalibur Qual Browser (Thermo Fisher Scientific), which is (proprietary) commercial software. An open-source alternative is ThermoRawFileParser (https://doi.org/10.1021%2Facs.jproteome.9b00328). Automated identification of oligonucleotides was accomplished using BioPharma Finder v5.0 (Thermo Fisher Scientific), which is (propriety) commercial software. An open-source alternative is attached in this dataset: three Excel VBA spreadsheets that may be used to in the identification of any MS feature. As Excel VBA spreadsheets, they are fully compiled and do not require any library code extensions or external links. The "Oligonucleotide MS Peak ID Given Sequence v8.xlsm" spreadsheet may be used to generate a list of theoretical RNaseT1 digest oligonucleotides and match observed precursor masses to candidate theoretical RNaseT1 digest oligonucleotides. Inputs are a single or list of observed masses and a target mRNA construct sequence. T...

Malaysia Consumer Price Index (CPI): Weights: H: MA: Meds, Vaccines & Other Products data was reported at 0.400 % in 2024. Malaysia Consumer Price Index (CPI): Weights: H: MA: Meds, Vaccines & Other Products data is updated yearly, averaging 0.400 % from Dec 2024 (Median) to 2024, with 1 observations. The data reached an all-time high of 0.400 % in 2024 and a record low of 0.400 % in 2024. Malaysia Consumer Price Index (CPI): Weights: H: MA: Meds, Vaccines & Other Products data remains active status in CEIC and is reported by Department of Statistics. The data is categorized under Global Database’s Malaysia – Table MY.I004: Consumer Price Index: 2010=100: Weights: Annual.

Malaysia Consumer Price Index (CPI): Health: MA: Medicines, Vaccines & Other Products data was reported at 129.500 2010=100 in Mar 2025. This records a decrease from the previous number of 129.600 2010=100 for Feb 2025. Malaysia Consumer Price Index (CPI): Health: MA: Medicines, Vaccines & Other Products data is updated monthly, averaging 121.600 2010=100 from Jan 2010 (Median) to Mar 2025, with 183 observations. The data reached an all-time high of 129.600 2010=100 in Feb 2025 and a record low of 99.100 2010=100 in Mar 2010. Malaysia Consumer Price Index (CPI): Health: MA: Medicines, Vaccines & Other Products data remains active status in CEIC and is reported by Department of Statistics. The data is categorized under Global Database’s Malaysia – Table MY.I001: Consumer Price Index: 2010=100.

Malaysia Consumer Price Index (CPI): Weights: H: MA: Medicines, Vaccines & Other Products data was reported at 0.400 % in Mar 2025. This stayed constant from the previous number of 0.400 % for Feb 2025. Malaysia Consumer Price Index (CPI): Weights: H: MA: Medicines, Vaccines & Other Products data is updated monthly, averaging 0.400 % from Jan 2024 (Median) to Mar 2025, with 15 observations. The data reached an all-time high of 0.400 % in Mar 2025 and a record low of 0.400 % in Mar 2025. Malaysia Consumer Price Index (CPI): Weights: H: MA: Medicines, Vaccines & Other Products data remains active status in CEIC and is reported by Department of Statistics. The data is categorized under Global Database’s Malaysia – Table MY.I003: Consumer Price Index: 2010=100: Weights.